A Randomized Phase II Pilot Study Prospectively Evaulating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer

Unresectable advanced or metastatic histologically or cytologically confirmed adenocarcinoma of the esophagus, stomach, or gastroesophageal junction (GEJ) and no brain metastases. Pts must not have received treatment for metastatic or unresectable disease. Measurable and/or non-measurable disease. HER-2 negative (if not already tested, will be performed with ERCC1 testing). Tumor available for ERCC1 (and HER-2, if needed) testing. Any prior neoadjuvant and adjuvant therapy for resectable disease at least 180 days prior to reg. Zubrod performance status 0-1. Within 28 days prior to registration: hemoglobin >/= 9 g/dL; ANC >/= 1,500/mcL; platelets >/= 100,000/mcL; total bilirubin </= 1.5 mg/dL; AST and ALT both </= 3.0 x IULN (5.0 x IULN for liver mets); serum creatinine < 1.5 mg/dL OR creatinine clearance > 60 ml/min. Pt must not have motor or sensory neuropathy > Grade 1 using CTCAE v4.0. Pt must not have plans to receive concurrent chemotherapy, radiotherapy, immunotherapy or any other type of therapy for treatment of cancer while on protocol treatment. Palliative radiation therapy alone must be completed at least 14 days prior to registration. Prestudy history/physical performed within 28 days prior to reg. Must not be pregnant or nursing. No other prior malignancy is allowed except the following: adequately treatment basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for five years.